Work

Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin(NPI-2358) in Patients with Solid Tumors or Lymphomas

Year: 2010

Type: article

Study design: Clinical Trial

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-10-1096

Authors: Monica M. Mita, Matthew A. Spear, Lorrin K. Yee, Alain C. Mita, Elisabeth I. Heath, Kyriakos P. Papadopoulos, Kristine C. Federico, Steven D. Reich, Ofelia Romero, Lisa Malburg, MaryJo Pilat, G. Kenneth Lloyd, Saskia T.C. Neuteboom, Gillian Cropp, Edward Ashton, Patricia M. LoRusso

Institutions: The Barbara Ann Karmanos Cancer Institute, Northwest Medical Specialties, Wayne State University

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2069433719

FWCI: 3.079

Cites: 18

Cited by: 105

Related to: 10